impact factor, citescore
logo
 

Full Papers

 

Clinical characteristics of anti-isoleucyl-tRNA synthetase antibody associated syndrome and comparison with different patient cohorts


1, 2, 3, 4, 5

 

  1. Department of Rheumatology, China-Japan Friendship Hospital, Beijing, China.
  2. Department of Rheumatology, Zhengzhou University First Af liated Hospital, Zhengzhou, China.
  3. Department of Rheumatology, China-Japan Friendship Hospital, Beijing, China.
  4. Department of Rheumatology, China-Japan Friendship Hospital, Beijing, China.
  5. Department of Rheumatology, China-Japan Friendship Hospital, Beijing, China. guochunwang@hotmail.com

CER14511
2022 Vol.40, N°3
PI 0625, PF 0630
Full Papers

purchase article

PMID: 34128807 [PubMed]

Received: 10/02/2021
Accepted : 29/03/2021
In Press: 08/06/2021
Published: 22/03/2022

Abstract

OBJECTIVES:
This study aimed to analyse the clinical features of anti-isoleucyl-tRNA synthetase (OJ) antibodies in Chinese patients and to compare with previously published cohorts. We reviewed the clinical data of anti-OJ antibody positive patients, including their long-term follow-up.
RESULTS:
Anti-OJ antibodies were present in 10 of 1269 (0.8%) patients with idiopathic inflammatory myopathies (IIMs), and 10/320 (3.1%) patients with anti-synthetase syndrome (ASS). Of the anti-OJ antibody-positive patients, 90% had interstitial lung disease (ILD), of whom three (30%) developed rapidly progressive ILD (RP-ILD). Half (50%) of the patients were febrile and developed myocardial involvement; 40% of patients experienced myositis, mechanic’s hands and arthritis. Compared to the anti-Jo-1 group, the levels of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) in the anti-OJ antibody-positive group were higher (p<0.05). From a review of the literature regarding the clinical features of anti-OJ, fever was more common in the eastern cohort (41.7% vs. 8.3%, p=0.002), whereas patients in western countries were more likely to develop arthritis (20.9% vs. 58.1%, p=0.001). With complete follow-up of the present cohort, 80% improved with treatment, including one patient who underwent lung transplant.
CONCLUSIONS:
The anti-OJ antibody occurred infrequently in Chinese patients, ILD was the major clinical feature, but myocardial injury was also a prominent associated complication. Anti-OJ positive patients were responsive to treatment.

DOI: https://doi.org/10.55563/clinexprheumatol/v2rbd0

Rheumatology Article